Antibodies to CTLA-4 like Ipilimumab and Tremelimumab, and antibodies to PD-1 like Pembrolizumab and Novilumab, were approved by the FDA for treatment of several types of cancers including melanoma, non-small cell lung cancer, and renal carcinoma [73]. Here, CTLA4 is linked to cancer.